Stockscreener 앱 받기
16.73
1.06%
-0.18
전일 마감가:
$16.91
열려 있는:
$16.98
하루 거래량:
263.40K
Relative Volume:
0.44
시가총액:
$861.85M
수익:
$107.46M
순이익/손실:
$105.90M
주가수익비율:
8.2511
EPS:
2.0276
순현금흐름:
$238.50M
1주 성능:
-0.18%
1개월 성능:
+4.43%
6개월 성능:
+11.91%
1년 성능:
+62.59%
1일 변동 폭
$16.65
$17.17
1주일 범위
$16.45
$17.17
52주 변동 폭
$8.33
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
명칭
Theravance Biopharma Inc
전화
650-808-6000
주소
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
16.73 | 861.85M | 107.46M | 105.90M | 238.50M | 2.0276 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2026-03-04 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2025-12-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-12 | 개시 | B. Riley Securities | Buy |
| 2024-08-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | 개시 | BTIG Research | Buy |
| 2024-01-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-15 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-08-25 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 개시 | JP Morgan | Overweight |
| 2020-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 개시 | Cowen | Outperform |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-06 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 개시 | H.C. Wainwright | Buy |
| 2018-03-29 | 재개 | Piper Jaffray | Overweight |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-12-21 | 개시 | Needham | Buy |
| 2016-11-03 | 개시 | Piper Jaffray | Overweight |
| 2016-10-12 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 개시 | Guggenheim | Buy |
| 2016-06-20 | 재확인 | Leerink Partners | Outperform |
| 2016-05-12 | 개시 | Leerink Partners | Outperform |
| 2016-05-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
모두보기
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
MSN Money - MSN
(TBPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Theravance's Q4 earnings and revenues miss estimates - MSN
Theravance stock declines around 17% in three months: Here's why - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc.TBPH - PR Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc.TBPH - FinancialContent
Theravance Biopharma (NASDAQ: TBPH) sets 2026 AGM votes on board, pay, auditor - Stock Titan
A Pivotal Quarter for Theravance Biopharma (TBPH): Milestone Cash Influx and a Transition to Pure Commercial Play - AlphaStreet
Theravance Biopharma (TBPH) Q4 earnings and revenues lag estimates - MSN
Here's why Theravance Biopharma (TBPH) is a strong momentum stock - MSN
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Laughing Water Capital Adds Theravance Biopharma to Portfolio in Q1 2026 - HarianBasis.co
Laughing Water Capital’s New Position: Theravance Biopharma, Inc. (TBPH) - Insider Monkey
Laughing Water Capital’s New Position: Theravance Biopharma (TBPH) - Yahoo Finance
Theravance and Mylan settle patent dispute with Eugia Pharma - MSN
How (TBPH) Movements Inform Risk Allocation Models - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Theravance Biopharma, Inc. (TBPH) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Theravance Biopharma, Inc. (TBPH) And Encourages Shareholders to Reach Out - ACCESS Newswire
Theravance Biopharma: A Special Situation With A 50-100% Likely Upside (TBPH) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Theravance Biopharma, Inc. (TBPH) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Theravance Biopharma (TBPH) Stock: What Investors Should Know (-0.75%) 2026-04-20Buy Signals - Xã Thanh Hà
B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14 - Insider Monkey
Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewir - The National Law Review
Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Impressive Revenue Growth and Strategic Collaborations Signal Potential Upside - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Theravance Biopharma, Inc. (TBPH) And Encourages Investors to Connect - ACCESS Newswire
Theravance Stock Declines Around 17% in Three Months: Here's Why - Yahoo Finance
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP - GlobeNewswire
Theravance Biopharma Inc (TBPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):